{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:06:42Z","timestamp":1793164002810,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1053\/j.semnuclmed.2004.11.006","type":"journal-article","created":{"date-parts":[[2005,3,12]],"date-time":"2005-03-12T17:04:54Z","timestamp":1110647094000},"page":"152-158","source":"Crossref","is-referenced-by-count":40,"title":["Teletherapy and radiopharmaceutical therapy of painful bone metastases"],"prefix":"10.1053","volume":"35","author":[{"given":"Edward B.","family":"Silberstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2004.11.006_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJM198507113130205","article-title":"The treatment of cancer pain","volume":"313","author":"Foley","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1359\/jbmr.2003.18.2.190","article-title":"Mechanisms of tumor metastasis to bone","volume":"18","author":"Reddi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7","article-title":"Metastases in carcinoma. Analysis of 1000 autopsied cases","volume":"23","author":"Abrams","year":"1950","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib4","series-title":"World Health Organ Tech Rep Ser, 804","first-page":"1","article-title":"Cancer pain relief and palliative care. Report of a WHO expert committee","year":"1990"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1991.9.3.509","article-title":"Bone metastases","volume":"9","author":"Nielsen","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for androgen-independent carcinoma of the prostate","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib8","first-page":"79","article-title":"Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer","volume":"43","author":"Sciuto","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib9","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1002\/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L","article-title":"The prevalence of pain in four cancers","volume":"60","author":"Greenwald","year":"1987","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0305-7372(89)90003-0","article-title":"Palliative irradiation of bone metastases","volume":"16","author":"Poulson","year":"1989","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/0277-5379(91)90254-B","article-title":"Palliation of bone metastases","volume":"27","author":"Hoskin","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y","article-title":"The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group","volume":"50","author":"Tong","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-8140(86)80191-8","article-title":"Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases","volume":"6","author":"Price","year":"1986","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0360-3016(97)00952-8","article-title":"The final report of the expert panel for the radiation oncology bone metastases working group of the ACR","volume":"40","author":"Rose","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/1097-0142(19860701)58:1<29::AID-CNCR2820580107>3.0.CO;2-2","article-title":"Single dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group Report","volume":"58","author":"Salazar","year":"1986","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF00254749","article-title":"Sr-89 therapy","volume":"12","author":"Blake","year":"1986","journal-title":"Eur J Nuc Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib17","first-page":"115","article-title":"Bone-seeking radiopharmaceuticals in cancer therapy","volume":"1","author":"Volkert","year":"1991","journal-title":"Advances Metals Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib18","first-page":"336","article-title":"A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186 (Sn)-HEDP","volume":"36","author":"Samaratunga","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1191\/0269216304pm887ra","article-title":"The pathophysiology of cancer-induced bone pain","volume":"18","author":"Urch","year":"2004","journal-title":"Palliat Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib20","first-page":"1358","article-title":"Radiopharmaceutical therapy for palliation of bone pain from osseous metastases","volume":"45","author":"Pandit-Taskar","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0306-4522(00)00110-X","article-title":"Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons","volume":"98","author":"Honore","year":"2000","journal-title":"Neuroscience"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrc747","article-title":"Molecular mechanisms of cancer pain","volume":"2","author":"Mantyh","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"suppl 2","key":"10.1053\/j.semnuclmed.2004.11.006_bib23","first-page":"10","article-title":"The treatment of painful osseous metastases with phosphorus-32-labeled phosphates","volume":"20","author":"Silberstein","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib24","first-page":"256","article-title":"Relative efficacy of 32P and 89Sr in palliation in skeletal metastases","volume":"40","author":"Nair","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib25","first-page":"226","article-title":"Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain","volume":"2","author":"Fettich","year":"2003","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib26","first-page":"117","article-title":"Biological investigations with radioactive calcium and strontium","volume":"11","author":"Pecher","year":"1942","journal-title":"U Cal Public Pharmacol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib27","first-page":"345","article-title":"Strontium-89 therapy for the pain of osseous metastases","volume":"26","author":"Silberstein","year":"1985","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0001-2998(05)80154-0","article-title":"Radionuclide therapy of intractable bone pain","volume":"22","author":"Robinson","year":"1992","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib29","first-page":"91","article-title":"An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy","volume":"3","author":"McEwan","year":"1990","journal-title":"Antibody Immunoconjugates Radiopharm"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1440-1673.2001.00871.x","article-title":"Strontium-89 treatment for prostate cancer bone metastases","volume":"45","author":"Zyskowski","year":"2001","journal-title":"Australas Radiol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/bjoc.2000.1610","article-title":"Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer","volume":"84","author":"Turner","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00006231-199609000-00011","article-title":"Radiosensitization with low-dose cisplatin enhances pain palliation in radioisotope therapy with strontium-89","volume":"17","author":"Sciuto","year":"1996","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0001-2998(05)80155-2","article-title":"Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases","volume":"22","author":"Maxon","year":"1992","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib35","first-page":"1511","article-title":"Efficacy of rhenium-186 etidronate in prostate cancer patients with metastatic bone pain","volume":"37","author":"Quirijnen","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-0038-1632262","article-title":"Comparison of rhenium-188, rhenium-186-HEDP, and strontium-89 in palliation of painful bone metastases","volume":"39","author":"Liepe","year":"2000","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib37","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2003.12.060","article-title":"Repeated bone-targeted therapy for hormone-refractory prostate carcinoma","volume":"21","author":"Palmedo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0001-2998(05)80156-4","article-title":"[153Sm] EDTMP","volume":"22","author":"Holmes","year":"1992","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1440-1673.1999.00716.x","article-title":"Strontium and samarium therapy for bone metastases from prostate carcinoma","volume":"43","author":"Dickie","year":"1999","journal-title":"Australas Radiol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib40","first-page":"61","article-title":"Treatment of metastatic bone pain with tin-117m stannic diethyltriaminepentaacetic acid","volume":"4","author":"Srivastava","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s002590100533","article-title":"A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer","volume":"28","author":"Dafermon","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"suppl","key":"10.1053\/j.semnuclmed.2004.11.006_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000475428","article-title":"A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone","volume":"26","author":"McEwan","year":"1994","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0090-4295(97)00326-9","article-title":"Painful bone metastases in hormone-refractory prostate cancer","volume":"50","author":"Malmberg","year":"1997","journal-title":"Urol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1517\/14656566.5.7.1555","article-title":"Pharmacological management of metastatic boney pain","volume":"5","author":"Viney","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Browne","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib46","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2004.11.006_bib47","first-page":"1097","article-title":"Bisphosphonates, pain and quality of life in metastatic breast cancer patients","volume":"90","author":"Roemer-Becuwe","year":"2003","journal-title":"Bull Cancer"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299804000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299804000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T09:09:10Z","timestamp":1586164150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299804000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0001299804000789"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2004.11.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}